Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375920 | 1.00 | REN (0.52) | REN | |
| SCHEMBL188719 | 1.00 | REN (0.52) | REN | |
| SCHEMBL13995940 | 0.96 | REN (0.48) | REN | |
| SCHEMBL13993323 | 0.91 | REN (0.46) | REN | |
| SCHEMBL10119254 | 0.88 | REN (0.52) | REN | |
| SCHEMBL8229073 | 0.88 | REN (0.54) | REN | |
| SCHEMBL14476482 | 0.88 | REN (0.54) | REN | |
| SCHEMBL10119597 | 0.87 | REN (0.50) | REN | |
| SCHEMBL220327 | 0.87 | REN (0.55) | REN | |
| SCHEMBL8228765 | 0.87 | REN (0.52) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| EP-3013836-B1 | PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED | PATHEON AUSTRIA GMBH & CO KG (AT) | 2018-06-20 | — | — | EP | disclosed |
| US-9550797-B2 | Preparation of Grignard reagents using a fluidized bed | PATHEON HOLDINGS I B.V. (NL) | 2017-01-24 | — | — | US | disclosed |
| US-9550797-B2 | Preparation of Grignard reagents using a fluidized bed | PATHEON HOLDINGS I B.V. (NL) | 2017-01-24 | — | — | US | disclosed |
| US-20160137669-A1 | PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED | PATHEON HOLDINGS I B.V. (NL) | 2016-05-19 | — | — | US | disclosed |
| US-20160137669-A1 | PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED | PATHEON HOLDINGS I B.V. (NL) | 2016-05-19 | — | — | US | disclosed |
| EP-2546243-B1 | METHOD FOR PREPARING ALISKIREN | ZHEJIANG TIANYU PHARMACEUTICAL CO LTD (CN) | 2015-01-07 | — | — | EP | disclosed |
| US-8664440-B2 | Method for preparing aliskiren and its intermediates thereof | ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD (CN) | 2014-03-04 | — | — | US | disclosed |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2013-11-21 | — | — | US | disclosed |
| US-8563279-B2 | Convergent synthesis of renin inhibitors and intermediates useful therein | DSM IP ASSETS B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-10-06 | — | — | US | disclosed |
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-10-06 | — | — | US | disclosed |
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-10-06 | — | — | US | disclosed |
| EP-2313386-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP Assets B.V. (NL) | 2011-04-27 | — | — | EP | disclosed |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | JLL/DELTA DUTCH NEWCO B.V. (NL) | 2011-01-13 | — | — | US | disclosed |
| WO-2010010165-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP ASSETS BV (NL) | 2010-01-28 | — | — | WO | disclosed |
| WO-2010010165-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | DSM IP ASSETS BV (NL) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009080773-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | DSM IP ASSETS B.V. (NL) | 2009-07-02 | — | — | WO | disclosed |
| US-20080306311-A1 | Method for Producing an Alpha-Chiral Chloromethyl Compound in a Pure Form | BASF SE (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008852-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | REN 1/4885 |
| US-20160137669-A1 | PREPARATION OF GRIGNARD REAGENTS USING A FLUIDIZED BED | GRM4, GRIA4, GRM2 | REN 527/4885 |
| US-20080306311-A1 | Method for Producing an Alpha-Chiral Chloromethyl Compound in a Pure Form | B2M, TPMT, MCCC2 | REN 91/4885 |
| US-20110244531-A1 | SYNTHESIS ROUTES TO 2(S),4(S),5(S),7(S)-2,7-DIALKYL-4-HYDROXY-5-AMINO-8-ARYL-OCTANOYL AMIDES | KHK, AGTR2, HK2 | REN 206/4885 |
| US-20130310577-A1 | CONVERGENT SYNTHESIS OF RENIN INHIBITORS AND INTERMEDIATES USEFUL THEREIN | REN, ACE, AGT | REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.